Dr. Harris specializes in the treatment of lung cancer, soft tissue sarcomas, skin cancers, and spine tumors. As an expert in the use of stereotactic body radiotherapy, Dr. Harris research focuses on the applications of advanced radiation technologies with systemic therapies to improve cancer care. He has received funding for investigator-initiated clinical trials on lung cancers as well as soft-tissue sarcomas. Dr. Harris serves on the steering committee of the University of California Lung Cancer Consortium, the SWOG sarcoma working group, and the UCI Data Safety Monitoring Board. A past winner of the Association of Residents in Radiation Oncology Educator of the Year award, Dr. Harris also serves as Associate Program Director for the radiation oncology residency.
- Stanford University School of Medicine, Stanford, CA, 2019
- California Pacific Medical Center, San Francisco, CA, 2015
- MD, Stanford University School of Medicine, Stanford, CA, 2014
- MPhil, Chemistry, University of Cambridge, Cambridge, UK, 2009
Certifications and Memberships
- ABR Board Certified
- American Society for Radiation Oncology (ASTRO)
- American Society of Clinical Oncology (ASCO)
- International Association for the Study of Lung Cancer
- SWOG Sarcoma Working Group
- SWOG Radiation Oncology Committee
- Churchill Scholar
- Gold Humanism Honor Society
- Alpha Omega Alpha Medical Honor Society
- UCI Radiation Oncology Residency ASTRO/ARRO Teaching Award
- Harris JP, JD Murphy, AL Hanlon, Le QT, Loo BW, Diehn M. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 8(4): 872-884.
- Harris JP, Chang-Halpenny CN, Maxim PG, Quon A, Graves EE, Diehn M, Loo BW. Outcomes of modestly hypofractionated radiation for lung tumors: pre- and mid-treatment positron emission tomography-computed tomography metrics as prognostic factors. Clin Lung Cancer 2015; 16(6): 475-485.
- Harris JP, Patel MI, Loo BW, Wakelee HA, Diehn M. A population-based comparative effectiveness study of chemoradiation regimens in stage III non-small cell lung cancer. Lung Cancer 2017; 108: 173-182.
- Harris JP, Chen MM, Orosco RK, Sirjani D, Divi V, Hara W. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. JAMA Otolaryngology Head and Neck Surg 2018; 144(4): 349-359.
- Harris JP, Nwachukwu C, Qian Y, Pollom E, Loo BW, Das M, Diehn M. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. Lung Cancer 2018; 124: 76-85.
- Harris JP, Saraswathula A, Kaplun B, Qian Y, Chan KCA, Chan ATC, Le QT, Owens DK, Goldhaber-Fiebert JD, Pollom E. Cost-effectiveness of screening for nasopharyngeal carcinoma for Asian-American men in the US. Otolaryngol Head Neck Surg 2019; 161(1): 82-90.
- Harris JP, Kashyap M, Humphreys JN, Chang DT, Pollom EL. The clinical and financial cost of mental disorders among elderly patients with gastrointestinal malignancies. Cancer Med 2020; 9(23): 8912-8922.
- Harris JP, Kashyap M, Humphreys JN, Chang DT, Pollom EL. Longitudinal analysis of mental disorders among elderly patients with gastrointestinal malignancies. J Natl Compr Canc Netw 2021; 19(2): 163-171.
- Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clin Lung Cancer 2022; 23(4): 333-344.
- Riviere P, Brazel D, Goshtasbi K, Kuan EC, Gao L, Harris JP. Comorbid immunosuppression in Merkel cell carcinoma, a retrospective database study. JAAD Int 2022; 8: 136-138.